Inclusion Criteria:

- Gastric or gastroesophageal junction adenocarcinoma cyto/histologically documented

- Disease progression/ recurrence after treatment with one prior single agent or
combination chemotherapy regimen for advanced / metastatic disease (last dose at
least 4 wks before study entry). Patients may have also received prior adjuvant
therapy if recurrence occurred > 6 months after adjuvant therapy completion

- Evidence of measurable disease by radiographic technique

- Adequate organ function.

Exclusion Criteria:

- Clinically relevant ascites (i.e. requiring paracentesis)

- Severe weight loss

- NCI CTCAE Grade 3 hemorrhage <4 weeks of starting study treatment

- Diagnosis of second malignancy within last 3 years

- History of or known brain metastases, spinal cord compression, or carcinomatous
meningitis

- Known HIV

- Serious acute or chronic illness

- Current treatment on another clinical trial

- Pregnant or breastfeeding